Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.
Tarih
2022Yazar
Morales-Barrera, Rafael
Powles, Thomas
Alva, Ajjai Shivaram
Ozguroglu, Mustafa
O'Donnell, Peter H.
Loriot, Yohann
Csoszi, Tibor
Vuky, Jacqueline
Plimack, Elizabeth R.
Matsubara, Nobuaki
Fradet, Yves
Geczi, Lajos
Gunduz, Seyda
Mamtani, Ronac
Bajorin, Dean F.
Liu, Chih-Chin
Imai, Kentaro
Moreno, Blanca Homet
Bellmunt, Joaquim
Balar, Arjun Vasant
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Makale [92796]